发明名称 |
Combination of BLyS inhibition and anti-CD 20 agents for treatment of autoimmune disease |
摘要 |
The invention relates to novel combination therapies involving BLyS or BLyS/APRIL inhibition and anti-CD20 agents for the treatment of autoimmune diseases. One preferred method is where the BLyS antagonist is a Fc-fusion protein which can be a TACI-Fc-fusion protein comprising the extracellular domain of TACI or a functional fragment thereof, a BAFF-R-Fc-fusion protein comprising the extracellular domain of BAFF-R or a functional fragment thereof, or a BCMA-Fc-fusion protein comprising the extracellular domain of BCMA or a functional fragment thereof. In the methods of the present invention some of anti-CD20 agents contemplated include RITUXAN®, ocrelizumab, ofatumumab (HuMax-CD20®), TRU-015, and DXL625, although any agent that binds to CD 20 may be suitable. The methods of the present invention reduce the levels of B cells in patients in need of such reduction, such as those suffering from autoimmune diseases. |
申请公布号 |
AU2008312406(B2) |
申请公布日期 |
2014.03.06 |
申请号 |
AU20080312406 |
申请日期 |
2008.10.16 |
申请人 |
ARES TRADING S.A.;ZYMOGENETICS, INC. |
发明人 |
PEANO, SERGIO;BROLY, HERVE;PONCE JR., RAPHAEL A.;GRAFFNER, HANS OTTO LENNART |
分类号 |
C07K16/28;A61K38/17;A61K39/395;A61P37/00;C07K19/00 |
主分类号 |
C07K16/28 |
代理机构 |
|
代理人 |
|
主权项 |
|
地址 |
|